Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Community study demonstrates Keppra’s use in various pain types

21.03.2003


New data shows that the antiepileptic drug Keppra (levetiracetam), when used alone and in combination with other treatments, provided relief to more than 90 percent of patients with a range of pain syndromes, from migraine headaches to neck and back pain. The study of 400 patients, conducted by the Statesville Pain Associates of Statesville, N.C., was presented today at the American Pain Society’s 22nd Annual Scientific Meeting.



"To date, studies of Keppra to treat pain have been conducted in small patient populations only. Our study of hundreds of patients showed that Keppra was well tolerated and has the potential to be an effective pain treatment alone or in combination with gabapentin, the current ’gold standard’ for the treatment of neuropathic pain," said Douglas Pritchard, M.D., pain specialist and lead investigator of the study. "As pain specialists, we’re always searching for more treatment options. It’s been encouraging to see this response to treatment in such a wide variety of pain states."

Each year chronic pain affects 70 million Americans, or approximately one in every four people, and contributes to 40 million doctor visits. The burden of pain also results in 515 million lost workdays, and accounts for $100 billion in medical expenses each year.1


Investigators determined that 372 of 400 patients involved in the study responded to Keppra, currently approved by the U.S. Food and Drug Administration for the adjunctive treatment of partial onset seizures in adults. Keppra was given as a stand-alone treatment or in combination with gabapentin, another antiepileptic drug (AED) used to treat pain, to 400 patients experiencing migraine headaches, neck, back, nerve, diabetic and complex regional pain syndromes.

This retrospective analysis was of 400 patients given Keppra over a six-month period as a stand-alone drug (n=30%) and in combination with gabapentin (n=70%). Five percent of the patients in this study were treated for migraine headaches and the others were treated for various types of pain including, neck pain (20%), back pain (40%), nerve pain (15%), diabetic pain (15%) and complex regional pain syndromes (5%). Keppra was titrated to dosages between 1,000 and 2,000 mg/day, throughout the duration of treatment (one to six months).

Participants also evaluated their own pain using the visual analog scale (VAS), in which pain is evaluated on a scale of 0-10, with 10 signifying the highest degree of pain. Before starting treatment with Keppra, patients rated their pain between 7 and 10, but within five to 10 days, their self-evaluated VAS scores fell to 5 and 6. The patients’ pain relief was also evaluated by a patient global assessment of pain indicating good pain relief as well as improved function and quality of life.

The most common side effects associated with the use of Keppra in this analysis were drowsiness and nausea.


About Statesville Pain Associates
The pain management team at Statesville Pain Associates strives to minimize patients’ pain, restore their ability to function and ultimately enable them to enjoy a better quality of life. Headed by Dr. Douglas Pritchard and Dr. Bobby Kearney, Statesville Pain Associates treats over 800 patients a month using a multidimensional and a multidisciplinary approach.

Jessica Balaban | EurekAlert!
Further information:
http://www.ncps-cpr.com

More articles from Health and Medicine:

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

nachricht Direct conversion of non-neuronal cells into nerve cells
03.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Nano-kirigami: 'Paper-cut' provides model for 3D intelligent nanofabrication

16.07.2018 | Physics and Astronomy

New players, standardization and digitalization for more rail freight transport

16.07.2018 | Transportation and Logistics

Researchers discover natural product that could lead to new class of commercial herbicide

16.07.2018 | Agricultural and Forestry Science

VideoLinks
Science & Research
Overview of more VideoLinks >>>